Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine) / UniQuest - LARVOL DELTA

Efficacy of Intralesional Acyclovir versus Quadrivalent Human Papillomavirus Vaccine for Treatment of Recalcitrant Cutaneous Warts: A Clinical Trial (EADV 2026) - No abstract available

Clinical • Dermatology

A Clinical Study of V540A in Healthy Female Participants (V540A-005) (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Merck Sharp & Dohme LLC | N=525 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal

Add-Vacc: Adding Male Single Dose HPV Vaccination to Female HPV Vaccination in Tanzania (clinicaltrials.gov) - P4 | N=10400 | Recruiting | Sponsor: London School of Hygiene and Tropical Medicine | Active, not recruiting ➔ Recruiting | Trial primary completion date: Nov 2025 ➔ Dec 2026

Enrollment open • Trial primary completion date • Human Papillomavirus Infection • Infectious Disease

Safety and Immunogenicity of V540B in Healthy Adults (V540B-002). (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Active, not recruiting ➔ Recruiting | Trial completion date: Nov 2026 ➔ May 2028 | Trial primary completion date: Nov 2026 ➔ May 2028

Enrollment open • Trial completion date • Trial primary completion date

The Role of Adjuvant Nonavalent HPV Vaccination After LLETZ in Patients with Isolated CIN2: A Controlled Cohort Study. (PubMed, Pathogens) - "Adjuvant 9vHPV administration after LLETZ for isolated CIN2 was associated with a clinically substantial lower absolute recurrence rate (2.03% vs. 5.71%, corresponding to a 64.6% relative risk reduction). Although this reduction did not achieve statistical significance (p=0.165) due to our small sample size and a low baseline recurrence rate in this isolated cohort, the effect size is highly comparable to broader CIN2+ studies. The study was likely underpowered to prove statistical significance, and larger multi-center studies are required to confirm the statistical value of adjuvant vaccination specifically in isolated CIN2 lesions."

Journal • Cervical Cancer • Gynecology • Human Papillomavirus Infection • Infectious Disease • Oncology

Real-World Effectiveness and Impact of Human Papillomavirus Vaccination in Males: A Comprehensive Review. (PubMed, Int J Infect Dis) - "Real-world evidence indicates that HPV vaccination substantially reduces anogenital and oral HPV infections and AGW in males. GNV programs further reduce HPV-related disease burden, reinforcing the public health significance of universal HPV vaccination programs worldwide."

Journal • Real-world evidence • Review • Dermatology • Gastrointestinal Disorder • Human Papillomavirus Infection • Infectious Disease • Oncology

Adult immunization. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Hepatitis B • Herpes Zoster • Infectious Disease • Inflammation • Influenza • Measles • Meningococcal Infections • Pertussis • Pneumococcal Infections • Respiratory Diseases • Respiratory Syncytial Virus Infections • Tetanus • Varicella Zoster

Parallel Declines in Human Papillomavirus 6/11-Related Disease Incidences: A National Study of Anogenital Warts and Recurrent Respiratory Papillomatosis in Norway. (PubMed, Open Forum Infect Dis) - "Anogenital warts incidence among females aged 15-29 decreased significantly from 1120.0 to 280.6 per 100 000 (annual percentage change: -10.3%), paralleling a sharp decline in recurrent respiratory papillomatosis from 3.7 to 0.6 per 100 000 (annual percentage change: -11.3%). These results strongly support vaccination impact in reducing the burden of HPV 6/11-related diseases, suggesting successful interruption of transmission pathways and substantial population-level protection."

Journal • Dermatology • Oncology

HPV Vaccination and Sexual Behaviors Among Middle-Aged United States Adults. (PubMed, Otolaryngol Head Neck Surg) - "HPV vaccination rates remain low among middle-aged adults despite expanded eligibility. Sexual activity, specifically having multiple partners, moderately increased vaccination likelihood. More robust predictors of vaccination include healthcare access, educational status, and socioeconomic factors, highlighting the importance of targeted educational initiatives and improved healthcare access to enhance vaccination uptake."

Journal • Oncology

Human Papillomavirus (HPV)-The Interplay between Vaginal Microbiota and HPV, along with its Prevention. (PubMed, Curr HIV Res) - "The relationship between the vaginal microbiome and HPV shows that preventive strategies such as probiotics and vaccination may significantly reduce infection risk and cancer progression."

Journal • Cervical Cancer • Infectious Disease • Oncology • Solid Tumor

Examining HPV- and HPV Vaccine-Related Cognitions and Acceptability in Immigrant Communities (AHNS 2026) - "Three recently developed, highly effective vaccines (nine-valent Gardasil, quadra-valent Gardasil, and Ceravix) are supported by the CDC and professional primary care organizations for the prevention of HPV-related infections and disease... Our study revealed significant heterogeneity in an urban immigrant population's understanding of HPV infection complications and HPV vaccine effectiveness in preventing oropharyngeal cancer. Drivers of vaccination hesitancy may include reduced awareness, poor understanding, and variable beliefs surrounding provider and vaccine availability, affordability, and government mistrust. Community-based education and interventions may improve awareness, facilitate understanding, and reduce hesitancy."

Clinical • Cervical Cancer • Head and Neck Cancer • Human Papillomavirus Infection • Infectious Disease • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Immunogenicity and safety of Papilloguard® 4, the first quadrivalent HPV vaccine combined with adjuvant system 04, versus Gardasil® in healthy 15-25-year-old individuals: a phase III, randomized, double-blind, non-inferiority trial. (PubMed, Vaccine) - "Papilloguard®, the first quadrivalent HPV vaccine combined with AS04, demonstrated non-inferior immunogenicity compared to Gardasil® for HPV types 6, 11, 16, and 18. Despite a higher incidence of local reactogenicity, likely associated with AS04, Papilloguard® showed enhanced immunogenicity while maintaining an acceptable overall safety profile, positioning it as a promising HPV vaccine."

Clinical • Head-to-Head • Journal • P3 data • Fatigue • Oncology • Pain

Impact of Implementing Alternative Human Papillomavirus (HPV) Vaccination Strategies in Kenya: A Modeling Study. (PubMed, MDM Policy Pract) - "A gradual scale-up of the current 2-dose quadrivalent vaccine (4vHPV) program would avert an additional 16,000 (14-18,000) cases (9%), increasing to 33,000 (28-37,000) cases (19%) if a multiage catchup is implemented in 2030. A 1-dose 9vHPV strategy would have more health benefits and save additional treatment costs compared with a 1-dose 2vHPV vaccine. Prompt 1-dose switch and rapid scale-up and adoption of a 9vHPV program should be priority policy decisions for Kenya."

Journal • Cervical Cancer • Oncology • Solid Tumor

Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC) in Women Living With HIV Aged 15-25 Years (clinicaltrials.gov) - P3 | N=450 | Active, not recruiting | Sponsor: Serum Institute of India Pvt. Ltd. | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Dec 2026 ➔ Dec 2027 | Trial primary completion date: Jun 2026 ➔ Dec 2026

Enrollment closed • Trial completion date • Trial primary completion date • Human Papillomavirus Infection • Infectious Disease • Oncology • CD4

A Phase III, Randomized, Double-Blind, Active-Controlled Non-Inferiority Trial Evaluating the Immunogenicity and Safety of Gardisun, a Quadrivalent Human Papillomavirus Vaccine, Compared with Gardasil® in Healthy Volunteers Aged 15-35 Years. (PubMed, Vaccines (Basel)) - "Most adverse events were mild and transient, with no vaccine-related serious adverse events reported. Gardisun demonstrated robust immunogenicity and a safety profile comparable to that of Gardasil®, supporting its potential as an accessible alternative quadrivalent HPV vaccine for broader vaccination programs in resource-limited settings."

Clinical • Head-to-Head • Journal • P3 data • Cervical Cancer • Human Papillomavirus Infection • Infectious Disease • Oncology • Oropharyngeal Cancer • Solid Tumor

Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023) (clinicaltrials.gov) - P3 | N=6000 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Trial completion date: Mar 2028 ➔ Nov 2029

Trial completion date • Infectious Disease • Oncology

Cost-Effectiveness of Nationwide HPV Vaccination in Girls in Kazakhstan: A UNIVAC-Based Analysis. (PubMed, Vaccines (Basel)) - " UNIVAC-based modelling suggests that introduction of a national HPV vaccination programme for 10-year-old girls in Kazakhstan using Gardasil-4 could substantially reduce cervical cancer burden and related mortality while generating considerable healthcare savings. These findings support the cost-effectiveness of nationwide HPV vaccination in Kazakhstan."

HEOR • Journal • Cervical Cancer • Infectious Disease • Oncology • Solid Tumor

Temporal trends in anal HPV infection among men who have sex with men attending sexual health clinics in three United States cities, 2018-2024. (PubMed, Sex Transm Dis) - "Among MSM aged 18-26 and 27-45 years, there was a decline in 4vHPV-type prevalent anal infections during 2018-2024. There was little to no decline in non-vaccine-type HPV prevalence during the same time period, suggestive of unchanging sexual exposure to HPV. These data demonstrate the impact of HPV vaccine on anal HPV infections in MSM.Summary: During 2018-2024, vaccine-type anal HPV infection declined by 13.4% and 5.6% annually among 18-26-year-old and 27-45-year-old men who have sex with men, respectively."

Journal • Gastrointestinal Disorder • Human Immunodeficiency Virus • Human Papillomavirus Infection • Infectious Disease • Oncology

Human Papillomavirus Vaccination in India: Paving the Way to Cervical Cancer Prevention. (PubMed, Ann Afr Med) - "Recent developments, including the introduction of the indigenous quadrivalent HPV vaccine Cervavac and its proposed inclusion in the Universal Immunization Programme (UIP) for girls aged 9-14 years, represent a significant milestone. However, challenges such as vaccine hesitancy, logistical barriers, and limited awareness must be addressed. A comprehensive approach integrating vaccination, screening, and public education is essential for achieving the World Health Organization's cervical cancer elimination targets."

Journal • Cervical Cancer • Infectious Disease • Oncology • Solid Tumor

Integrating Adjuvant HPV Vaccination into Cervical Dysplasia Management After LLETZ/Conization. (PubMed, J Clin Med) - "Background: In this study, we evaluated the effects of the nonavalent Gardasil® vaccine in a heterogeneous cohort of women who underwent conization or LLETZ for various degrees of CIN, aiming to assess the adjuvant effect of vaccination on HPV clearance...Logistic regression showed that, with increasing age, the likelihood of healing after vaccination decreased by approximately 9% per additional year, and non-16/18 HPV-positive women had a 5.5-fold higher chance of healing after vaccination compared with those HPV-positive for 16 and 18 genotypes. Adjuvant prophylactic HPV vaccination in the context of surgical treatment for cervical precancerous lesions is significantly associated with a reduced risk of lesion recurrence and HPV persistence/reinfection when administered prior to or at the same time as the excisional procedures."

Journal • Cervical Cancer • Gynecology • Oncology

Cost-effectiveness of human papillomavirus vaccination in Jordan: A modelling study. (PubMed, Vaccine) - "A single dose of Cecolin® could prevent more than half of the expected lifetime cervical cancer cases and deaths in Jordan and is very likely to be cost saving. Cervarix™ may be more impactful than Cecolin® but this depends on cross-protection assumptions. Continued multi-sectoral engagement and donor collaboration will be essential to ensure sustainable integration into the national immunization programme."

HEOR • Journal • Cervical Cancer • Oncology • Solid Tumor

Genotype Distribution of Human Papillomavirus (HPV) Types in Oral Gargle Specimens among Men Living with HIV in Mexico, Brazil, and Puerto Rico: a Cross-Sectional Study. (PubMed, J Infect) - P3 | "Oral HPV genotyping in men with HIV reveals distinct oncogenic patterns, underscoring the need to monitor long-term OPSCC risk."

Clinical • Journal • Observational data • Human Immunodeficiency Virus • Human Papillomavirus Infection • Infectious Disease • Oncology • Oropharyngeal Cancer • CD4

Towards Global HPV Eradication: Single-Dose HPV Vaccination vs. Pseudoscience. (PubMed, Pathophysiology) - "Furthermore, the hypothesis implicating a pathogenic role for aluminum adjuvants was unsupported by experimental evidence; HANS animal models were flawed methodologically and unreproducible experimentally. In summary, we believe that implementing worldwide HPV vaccination strategies, including gender-neutral and single-dose programs, as well as denouncing pseudoscientific claims hold the potential to eliminate high-risk HPV types globally."

Journal • Cervical Cancer • Immunology • Infectious Disease • Measles • Oncology • Solid Tumor

Optimal cervical cancer screening strategies for unvaccinated and HPV-vaccinated cohorts in the United States: a comprehensive comparative modeling analysis. (PubMed, Lancet Reg Health Am) - "We used three independent models calibrated to US data to simulate three birth cohorts: unvaccinated females born in 1980, females born in 1993 (predominantly offered bivalent/quadrivalent HPV vaccines), and females born in 2003 (predominantly offered nonavalent HPV vaccine)...This would reduce harms while remaining more effective than current guidelines in pre-vaccine cohorts. US National Cancer Institute."

Journal • Cervical Cancer • Oncology • Solid Tumor

HPV Prevalence Among Inuit Women in Northern Quebec, Canada: A Pre- and Post-Vaccination Analysis. (PubMed, J Low Genit Tract Dis) - "The quadrivalent HPV vaccine has reduced HPV 16/18 prevalence in the targeted younger population. Continued surveillance is warranted, particularly for nonvaccine high-risk types."

Journal • Cervical Cancer • Human Papillomavirus Infection • Infectious Disease • Oncology • Solid Tumor